Nicholas Investment Partners LP Purchases 63,640 Shares of Abivax SA Sponsored ADR $ABVX

Nicholas Investment Partners LP lifted its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 327.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,068 shares of the company’s stock after acquiring an additional 63,640 shares during the quarter. Nicholas Investment Partners LP owned 0.11% of Abivax worth $11,202,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. WPG Advisers LLC raised its holdings in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after acquiring an additional 253 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new position in Abivax in the fourth quarter valued at about $67,000. Finally, Assetmark Inc. purchased a new position in Abivax in the fourth quarter valued at about $84,000. 47.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ABVX. Wolfe Research set a $136.00 target price on Abivax in a research note on Wednesday, June 3rd. Morgan Stanley dropped their price target on Abivax from $145.00 to $132.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 2nd. Wedbush upgraded Abivax from an “underperform” rating to a “neutral” rating and dropped their price target for the stock from $110.00 to $90.00 in a research note on Tuesday, June 2nd. Oddo Bhf restated an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Finally, Barclays boosted their price target on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $130.08.

Abivax Stock Down 4.3%

Shares of NASDAQ ABVX opened at $96.55 on Friday. The business’s 50 day moving average price is $116.01 and its 200 day moving average price is $119.12. The firm has a market cap of $7.69 billion, a P/E ratio of -18.53 and a beta of 0.69. Abivax SA Sponsored ADR has a 52 week low of $5.69 and a 52 week high of $148.83.

Abivax (NASDAQ:ABVX) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. As a group, research analysts expect that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.